| Condensed Consolidated Statements Of Cash Flows |
| Net income |
153M |
| Adjustments to reconcile net income to net cash provided by operating activities: |
| Depreciation and amortization |
632M |
| Provision for doubtful accounts |
| Deferred income tax expense |
32M |
| Stock-based compensation expense |
51M |
| Impairment of long-lived assets and goodwill, and restructuring charges, net |
| Fair market value adjustments related to interest rate swap and LIBOR cap agreements |
| Amortization of debt discount and debt issuance costs |
33M |
| Litigation and investigation costs |
291M |
| Pre-tax loss from discontinued operations |
5M |
| Other items, net |
-3M |
| Changes in cash from operating assets and liabilities: |
| Accounts receivable |
-1.16B |
| Inventories and other current assets |
-95M |
| Income taxes |
-1M |
| Accounts payable, accrued expenses and other current liabilities |
-35M |
| Other long-term liabilities |
48M |
| Payments against reserves for restructuring charges and litigation costs |
-132M |
| Net cash provided by (used in) operating activities from discontinued operations, excluding income taxes |
1M |
| Net cash provided by operating activities |
851M |
| Cash flows from investing activities: |
| Purchases of property and equipment-continuing operations |
| Construction of new and replacement hospitals |
| Purchases of businesses or joint venture interests |
| Proceeds from sales of facilities and other assets - discontinued operations |
573M |
| Proceeds from sales of marketable securities, long-term investments and other assets |
36M |
| Other items, net |
3M |
| Net cash used in investing activities |
-150M |
| Cash flows from financing activities: |
| Repayments of borrowings |
-112M |
| Proceeds from borrowings |
4M |
| Repurchases of common stock |
| Cash dividends on preferred stock |
| Distributions paid to noncontrolling interests |
-151M |
| Other items, net |
9M |
| Net cash used in financing activities |
-408M |
| Net increase (decrease) in cash and cash equivalents |
293M |
| Cash and cash equivalents at beginning of period |
356M |
| Cash and cash equivalents at end of period |
649M |
| Supplemental disclosures: |
| Interest paid, net of capitalized interest |
-596M |
| Income tax refunds, net |
-33M |
